BIOSPAIN 2026

Want to tilt the odds in your favor on the roadshow? Hear it straight from the source: Spain’s top biotech VCs will unveil their investment playbooks—how they judge scientific risk, vet team credentials and experience, assess development plans, and prioritise therapeutic areas. Each investor gets a brisk, 9-minute spotlight to explain what truly moves the needle. Walk away with a sharper sense of how opportunities are valued and what to emphasize in your pitch.

Engineered living materials (ELMs) are composed, either entirely or partly, of living cells. ELMs entirely composed of living cells are called biological ELMs and they self-assemble via a bottom-up process – e.g. synthetic morphogenesis for organoids’ production. ELMs only partly composed of living cells are called hybrid living materials (HLMs) and are built with a top-down process with integrated polymers or scaffolds. In both cases, the cellular components extract energy from the environment to form or assemble the material itself, and to adapt its morphology and function to environmental stimuli. This endows these materials with a combination of properties not present in any non-living material: self-regeneration, adaptation to environmental clues, longevity and environmental sustainability. By being alive, ELMs represent a fundamental change in materials’ production and performance, enabling new, better or similar functionalities, compared to traditional materials but with decreased costs and environmental impact. ELMs have the potential to transform virtually every modern endeavour from healthcare to infrastructures to transportation.

Representante de Cocoon?
Representante de Regemat3D?
Representante de BASF

Following the publication of the proposed Biotech Act I Regulation, the European Commission has launched a consultation process for the future Biotech Act II, which will focus on industrial policy and on building a broad, forward-looking biotechnology ecosystem.
In this session, organised by AseBio, we will examine the opportunities presented by Biotech Act II to advance biomanufacturing and biotechnology innovation in Europe, while also addressing the regulatory, financing, and scale-up challenges facing the sector.

Estado ponentes: 
Moderador: Ion Arocena, General Director of AseBio
Miguel Ángel Pavón, Directorate-General for Industrial Strategy and Small and Medium-sized Enterprises (SMEs), Ministry of Industry and Turism – mandada invitación

• Mrs Kristin Schreiber, Director Chemicals, Bioeconomy and Retail, DG GROW.F, European Commission – mandada invitación
• Joerg Lindemann - MD / Site Manager WACKER
• Ana Maria Bravo-Angel, Director of Public Affairs at IFF - mandada invitación